пятница, 19 августа 2016 г.

Valeant Gets Lenders' Blessing to Loosen Debt Requirements

Valeant Gets Lenders' Blessing to Loosen Debt Requirements


Valeant Pharmaceuticals International Inc. received support from a majority of its lenders to loosen terms on its credit agreement, giving it additional flexibility to tackle its $30 billion debt load, according to a company statement on Thursday. Under the amendment, the drugmaker will be able to relax a condition that governed a measure of its earnings relative to interest expense, will gain the ability to sell more of its assets, and will be allowed to issue secured bonds with shorter maturities and other debt to repay term loans.



from Biotech News